4.6 Article

MicroRNAs in immune regulation-Opportunities for cancer immunotherapy

期刊

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2010.02.002

关键词

MicroRNA; Type-1 helper (Th1); Cancer; Cancer immunology; High-mobility group box (HMGB)1

资金

  1. NCI NIH HHS [1P01CA132714, P01 CA101944-02, P01 CA101944, P01 CA132714-01A18081, P01 CA132714, P01 CA 101944] Funding Source: Medline
  2. NCRR NIH HHS [1U54RR023506] Funding Source: Medline
  3. NINDS NIH HHS [R01 NS055140, 1R01NS055140, 2P01 NS40923, P01 NS040923-070005, P01 NS040923, R01 NS055140-03] Funding Source: Medline

向作者/读者索取更多资源

Endogenously produced microRNAs are predicted to regulate the translation of over two-thirds all human gene transcripts. Certain microRNAs regulate expression of genes that are critically involved in both innate and adaptive immune responses. Immune cells represent a highly attractive target for microRNA gene therapy approaches, as these cells can be isolated, treated and then reintroduced into the patient. In this short review, we discuss how recent discoveries on the roles of microRNAs in immune-regulation will advance the field of cancer immunology and immunotherapy. Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a. In macrophages. miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs and miR-34C and miR-214 as Damage Associated Molecular Pattern Molecules-associated miRs. We have also demonstrated that the ability of tumors to serve as targets for cytolytic effectors is regulated by miR-222 and miR-339. (C) 2010 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据